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 CLINICAL AND SYSTEMATIC REVIEWS 
 INTRODUCTION 
 Irritable bowel syndrome (IBS) is a chronic debilitating functional 
illness aff ecting more than 10 % of the population ( 1 ). Patients 
are diagnosed if they have recurring pain or discomfort in the 
lower abdomen, accompanied by altered stool form or frequency. 
Importantly, these symptoms occur in the absence of gross struc-
tural abnormalities. As biomarkers are lacking, IBS patients are 
grouped according to symptom-based criteria, with the current 
ROME classifi cation system subcategorizing patients as diarrhea 
predominant (IBS-D), constipation predominant (IBS-C), alter-
nating (IBS-A), or unspecifi ed (IBS-U) ( 1 ). Th e sensory symptoms 
of pain / discomfort are the most debilitating aspects to patients, 
yet are the least responsive to pharmacological treatment. IBS is 
currently considered as a neurological motility disorder resulting 
from alterations in the brain gut axis; however, the underlying 
mechanisms are unclear. Th e gastrointestinal (GI) tract contains 
extensive immune and nervous systems (outlined in  Figure 1 ), 
and alterations in the immune system are increasingly implicated 
in the pathogenesis of IBS ( 2 ). Th is was fi rst observed in patients 
that attributed their symptoms to prior exposure to a GI patho-
gen, termed post-infectious IBS, but more recently has also been 
shown in other IBS cohorts ( 2,3 ). Surprisingly, little is known of 
how changes in the immune function aff ect the nerve function 
in IBS. Th is is despite the substantial body of work showing that 
luminal contents and infl ammatory mediators modulate intes-
tinal nerve function in animal models, demonstrating that the 
function of these nerves remains altered long aft er resolution of 
the infl ammatory insult ( 4,5 ). Th is review focuses on how alter-
ations in the immune system of IBS patients modulate GI nerve 
activity and symptoms. Understanding this is essential for the 
development of novel therapies against the underlying etiology 
of the disease. 
 ROLE OF MICROBIOTA IN IBS 
 Th e GI tract contains a dense society of commensal bacteria, 
estimated to number in trillions. Th e relationship between the 
host and the microbe is immunologically complex, as com-
mensals comprise a balance between benefi cial and harmful 
strains in health. Any disruptions in this homeostasis leads to 
dominance by pathogenic species rather than normal intesti-
nal fl ora and, thus, decreased variation in bacterial strains in 
patients with IBS ( 6 – 9 ). Microbiota are most abundant in the 
colon where a striking switch in strain predominance from 
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Gram-positive aerobes to Gram-negative anaerobes occur, and 
the colon is therefore the major site of fermentation and subse-
quent production of organic acids and gases ( 10 ). Bacteria, their 
shed proteins, and / or fermentation products, such as hydrogen 
sulfi de and methane, modulate the activity of sensory nerves 
innervating the lower GI tract ( Figure 2 ) ( 11 – 15 ). Rectal infu-
sion of fecal supernatants from IBS patients sensitizes mice to 
colorectal distension, which is suggested to occur via microbe-
secreted serine proteases, which activate protease-activated 
receptor-2 on nerve endings ( 16 – 18 ). Th e direct eff ects on sen-
sory nerves may also be compounded by activation of the innate 
and adaptive immune responses, as suggested by the elevated 
levels of antibodies against bacterial fl agella in IBS patients 
( 19,20 ). Oral probiotic preparations aimed at restoring the 
 “ healthy commensal biota balance ” have been met with much 
enthusiasm by IBS patients, and studies have shown  Lactoba-
cilli and  Bifi dobacteria preparations both modulate immune 
function and improve IBS symptoms ( 21 – 23 ). Furthermore, 
rectal infusion of bacteria, particularly the  Lactobacillus strains, 
also induces analgesic eff ects, possibly due to upregulation of 
μ -opioid receptors on epithelial cells rather than direct actions 
on GI nerves ( 24,25 ). Recent studies indicate that treatment 
with a nonabsorbable broad spectrum antibiotic provided 
relief for IBS-D patients ( 26,27 ). However, much remains to be 
understood regarding how changes in microbiota contribute to 
IBS symptoms, including details of the immunological aspects 
underpinning the homeostasis of the symbiotic relationship 
between the host and the bacteria, which bacterial strains are 
the most pathogenic in IBS, and how they interact with nerve 
endings to cause altered sensations. As such, considerable con-
tention surrounds the mechanistic role of probiotics and antibio-
tics in the treatment of IBS ( 3,28 – 30 ). 
 ARE BARRIER DEFENSES ALTERED IN IBS? 
 Intestinal barrier defenses provide the fi rst line of protection in 
the GI tract. Th e lumen is lined with a thick layer of mucus, which 
comprises a complex mixture of glycoproteins, including mucins 
and bacteriocidal enzymes, and also large amounts of secretary 
immunoglobulin A (IgA) in most individuals ( Figure 1 ). Th e 
mucus coats a monolayer of polarized epithelial cells that regulate 
permeability through the formation of tight junctions, termed the 
epithelial barrier. Th e epithelial barrier has a prominent role in 
the exchange of nutrients and fl uids in the intestine, but is rela-
tively impervious to larger molecules and organisms in health. 
Several studies now indicate barrier defenses are altered in IBS 
patients, with increased intestinal permeability, increased fecal 
concentrations of the bacteriocide  β -defensin-2, and increased 
expression of mucosal proteins MUC20 and PARM1 ( 31 – 39 ). 
Single-nucleotide polymorphisms in  CDH1 , which encodes the 
tight junction protein E-cadherin, are associated with increased 
risk of post-infectious IBS ( 40 ). Detailed molecular studies of the 
epithelial barrier indicate the expression and subcellular distri-
bution of tight junction proteins are substantially altered in IBS 
patients ( 41 – 44 ), and impaired intestinal permeability has been 
shown to correlate with pain / discomfort and / or bowel habit 
( Table 1 ) ( 34,37,41,43 ). However, impaired barrier defenses are 
unlikely to directly cause pain, but instead ease access of luminal 
contents to the GI wall, promoting infl ammatory responses and 
modulating sensory-motor function. 
 ALTERATIONS IN INNATE IMMUNITY 
 Mast cells 
 Mast cells are the most studied population of immune cells in 
IBS. Th ese leukocytes contain granules and are typically asso-
ciated with allergic-type responses. When activated, mast cells 
secrete a complex mixture of infl ammatory mediators, including 
proteases, prostaglandins, histamine, and cytokines / chemokines, 
many of which modulate the intestinal nerve activity ( Figure 1 ). 
IBS patients have increased serum concentrations of interleukin 
(IL)-8, a chemokine primarily responsible for the attraction of 
mast cells and granulocytes ( 45 – 47 ). However, reports of vari-
ation in the absolute number of mast cells in the intestine are 
confl icting, as a similar number of studies indicate mast cell 
numbers are increased or unchanged in IBS patients ( Table 2 ) 
( 44,48 – 67 ). In those studies that observed increased mast cell 
numbers, correlations with symptoms are also mixed ( Table 1 ) 
( 37,41,50,52,53,55,59,63 ). Despite this contention, the absolute 
number of mast cells may not be the defi ning characteristic of 



























 Figure 1 .  Alterations in the gastrointestinal (GI) immune system in irritable 
bowel syndrome. Nonspecifi c defenses are provided by mucous, the 
epithelial barrier, and innate immune cells, including macrophages, 
dendritic cells, natural killer (NK) cells, mast cells, and eosinophils. 
Specifi c defenses are cell mediated (T-cell dominant) or humoral (B-cell 
dominant) responses directed against repeated exposure to specifi c 
antigen. Dendritic cells are antigen-presenting cells that phagocytose 
antigenic material at the site of infection and travel to lymph nodes where 
they present antigen to T cells, and are therefore key mediators between 
the innate and adaptive immune response. Repeated exposure to antigen 
activates adaptive B and T cells in lymph nodes, which are selectively 
home to the GI tract via expression of  α 4 β 7 . Intestinal nerves are modulated 
by antigen and also immune mediators secreted by a number of different 
immune cell types. CNS, central nervous system; Ig, immunoglobulin; 
MadCAM-1, mucosal addressin cell adhesion molecule-1. 
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( 62,69 – 71 ). However, mast cell degranulation is a complex proc-
ess, which also occurs independently of IgE, as diff erent mast cell 
activators are able to modulate the selective release of a diverse 
range of mast cell mediators ( 72 ). 
 Antigen-presenting cells 
 Antigen-presenting cells , including macrophages and dendritic 
cells, are little investigated in IBS. Macrophages are primarily 
involved in phagocytosis in the GI tract, but also have antigen-
presenting capabilities and secrete an array of cytokines that 
activate nerve endings ( Figures 1 and 2 ). Th e concentration of 
macrophage-attracting chemokines secreted by intestinal biop-
sies and the numbers of CD68  +  macrophages are decreased 
in IBS compared with healthy subjects, possibly indicating an 
impaired capacity to respond to antigenic material ( Table 2 ) 
( 62,64,73 ). Macrophages express Toll-like receptors (TLRs) and 
decreased macrophage numbers in contrast with recently found 
increased expression of TLR4 and TLR5 in colonic biopsies from 
IBS patients ( 74 ). However, epithelial cells also express TLRs, 
and as immune cells were not isolated in this study it is not clear 
whether the increased expression was observed on epithelial or 
immune cells, or both ( 75 ). At least two subsets of macrophages 
have been described, M1 and M2, based on functional diff er-
ences, but much remains to be learned regarding appropriate 
closer proximity to colonic nerve endings in IBS patients, a fi nd-
ing that correlated strongly with severity and frequency of pain 
( 55 ). Further, supernatants from mucosal biopsies from IBS 
patients are more likely to activate intestinal nerves than those 
from healthy subjects ( 52,54,56,66,68 ). Th is nerve activation is 
dependent on mast cell-derived mediators, including serine pro-
teases acting on protease-activated receptor-2, histamine acting 
on its H 1 receptor, and serotonin acting on its 5-HT 3 receptor 
( Figure 2 ), and occurs regardless of whether changes in absolute 
mast cell numbers are observed or not. Most interestingly, these 
alterations are observed across IBS-D, -C, and -A patients, sug-
gesting common pain inducing mediator(s), although by default 
this excludes a role in the diff erent motility patterns observed in 
these patient cohorts and concentrations of these mediators oft en 
do not correlate with symptoms ( Table 1 ) ( 37,41,52,55 ). Of note, 
IBS patients hypersensitive to colonic distension recently showed 
benefi t from treatment with the mast cell stabilizer and H 1 recep-
tor antagonist Ketotifen; however, the underlying mechanisms 
are unclear, as this treatment did not alter mast cell numbers or 
cultured secretion of histamine or tryptase ( 67 ). A key remaining 
question is what is driving the mast cell degranulation observed 
in IBS patients? Levels of IgE, the classical mast cell degranula-
tor, are typically unaltered in serum or colonic biopsies in IBS 





























 Figure 2 .  Altered immunity in irritable bowel syndrome has differential affects on neural activity with excitatory or inhibitory consequences. Bacteria, their 
products, and immune mediators bind to receptors on nerve endings. These receptors may either directly modulate nerve fi ring or may couple to effector 
ion channels to regulate the excitability of the nerve ending. The second messenger pathways involved in this coupling in the gastrointestinal (GI) tract are 
largely unknown. The fi ring of action potentials is the net result of excitatory and inhibitory inputs. IL, interleukin; TNF- α , tumor necrosis factor- α . 
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markers to diff erentiate them ( 76 ). Th e involvement of diff erent 
macrophage subtypes may apply in IBS, as CD163 is upregu-
lated on monocytes aft er activation and there is a much higher 
ratio of CD163:CD68 numbers in the colon of healthy subjects 
compared with IBS patients ( 62 ). 
 Eosinophils 
 Eosinophils are typically associated with allergic responses, but 
no changes in numbers in blood or intestinal biopsies or the 
 in situ levels of eosinophil cationic protein are observed in IBS 
( 50,77 – 79 ) ( Table 2 ). However, several studies have linked eosi-
nophil numbers with functional dyspepsia, a functional GI disor-
der associated with upper abdominal discomfort and disordered 
motility ( 79,80 ). Little is known about the eff ects eosinophil-
derived mediators have on GI nerves. 
 ALTERATIONS IN ADAPTIVE IMMUNITY 
 Repeated exposure to the same antigen activates the adaptive 
immune system, whereby T and B cells quickly migrate from 
lymph nodes via the blood to sites of infection and mount stronger 
responses against specifi c antigen ( Figure 1 ). Migration of immune 
cells from the blood to the GI tract is dictated by chemokine gra-
dients and the binding of integrins to their specifi c receptors in 
the gut wall. Th e classic homing markers for lymphocytes are the 
interaction between MaDCAM-1 (mucosal addressin cell adhe-
sion molecule-1) in the gut wall and the integrin complex  α 4 β 7 
on the cell surface of lymphocytes. MaDCAM-1 expression is yet 
to be investigated in IBS patients and little is also known about 
chemokines, with only one report fi nding decreased expression 
of CCL2, CXCL9, and CXCL10 in mucosal biopsies from IBS 
patients ( 73 ). 
 T cells 
 Circulating T cells numbers are unaltered in IBS, but studies 
indicate a greater proportion of T cells are homing to the GI 
tract and reside within the GI wall in IBS patients compared 
with healthy subjects ( Figure 1 and  Table 2 ) ( 16,17,23,49 – 51,
53,55,63 – 65,81 – 85 ). Circulating T-helper (T H ) and cytotoxic T 
cells and T cells residing in the colon wall of IBS patients are 
more likely to be in an activated state, as they have increased 
expression of the activation markers CD69 and HLA-DR ( 82 ). 
Increased T-cell numbers correlate with motility-related symp-
toms in biopsies from the descending colon, but this was not 
observed in rectosigmoid biopsies ( Table 1 ) ( 51,53,63 ). Th ere 
is considerable divergence regarding the blood cytokine profi le 
in IBS, with some suggesting a predominating T H type 1 (T H 1) 
phenotype ( ↑ tumor necrosis factor- α (TNF- α ), IL-1 β , IL-12, 
IL-6, and  ↓ IL-10) ( 23,45 – 47,82,85 – 89 ), whereas others show 
a shift  toward a predominating T H 2 allergy-type phenotype 
( ↑ IL-5, IL-10, IL-13, and  ↓ TNF- α ;  Table 3 ) ( 78,84,90 ). On the 
other hand, some investigations fail to observe any change in 
cytokine concentrations ( 91 ). Blood levels of IL-1 β , TNF- α , and 
IL-6 correlate positively with IBS symptoms, whereas negative cor-
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Genotyping studies of IBS patients indicate they are more likely 
to have alleles associated with excessive production of IL-6, IL-2, 
TNF- α , and TNFSF15, a member of the TNF family, whereas 
a recent meta-analysis indicated high IL-10 producers are less 
likely to develop IBS ( 40,90,92 – 96 ). Classifi cation of patients 
according to the IBS subtype is rarely performed, but when 
this is done clear diff erences in immune profi le are observed 
with increased concentrations of T H 1-type cytokines, including 
TNF- α and IL-1 β , detected alongside typical T H 2 cytokines, such 
as IL-10, in IBS-D ( 85,87,88 ). Th e lack of polarization toward 
a T H 1 or T H 2 axis indicates the nature of immune activation in 
IBS is not straightforward but instead likely to be a complex 
pheno menon incorporating several distinct cell types and / or 
possibly cells with plasticity of function ( 97 ). 
 T REG are currently little investigated in IBS, with only one 
report showing that numbers and suppressive capabilities of 
blood and colon T REG are unaltered in IBS ( 98 ). Th e T H 17 axis 
is also yet to be studied in detail, and although the functions of 
T H 17 cytokines in intestinal homeostasis are controversial IL-17 
has been shown to sensitize sensory nerves in the somatosensory 
system ( 99,100 ). Understanding the role and relationship of these 
cell types is currently of great interest in a number of infl amma-
tory disease states, such as infl ammatory bowel disease ( 101 ), 
but is also very likely to provide vital information regarding the 
maintenance of the low grade but chronic immune activation 
observed in IBS patients. Th is may be especially of interest, as we 
better appreciate the likely phenomenon of  “ post-infl ammatory ” 
IBS ( 2,102,103 ). 
 Table 3 .  Changes in circulating immune profi les in IBS observed 
plasma / serum or peripheral blood mononuclear cells 
 Cytokine  Plasma / serum  PBMC 
 TNF- α  ↑ ( 86,89 ) 
 ↓ ( 84 ) 
 ↔ ( 45,46,91 ) 
 ↑ ( 85,87,88 ) 
 ↔ ( 90 ) 
 IL-1 β  ↑ ( 89 ) 
 ↔ ( 46,91 ) 
 ↑ ( 82,85,87,88 ) 
 ↔ ( 90 ) 
 IL-12  ↑ ( 89 ) 
 ↔ ( 46,91 ) 
 ↑ ( 23,87 ) 
 IL-2  ↔ ( 46 )  
 sIL-2R   ↑ ( 87 ) 
 IFN- γ  ↔ ( 46,89 )  ↔ ( 82,87 ) 
 IL-6  ↑ ( 45 – 47,89 ) 
 ↔ ( 91 ) 
 ↑ ( 85,87,88 ) 
 sIL-6R  ↑ ( 45 )  
 IL-4  ↔ ( 46 )  
 IL-5  ↔ ( 46 )  ↑ ( 78 ) 
 IL-10  ↓ ( 86 ) 
 ↔ ( 45,46,89,91 ) 
 ↑ ( 87,88,90 ) 
 ↓ ( 23 ) 
 ↔ ( 82 ) 
 IL-13  ↔ ( 46,89 )  ↑ ( 78 ) 
 IL-8  ↑ ( 45,46,89 ) 
 ↔ ( 91 ) 
 ↔ ( 87 ) 
 IBS, infl ammatory bowel syndrome; IFN, interferon; IL, interleukin; PBMC, 
peripheral blood mononuclear cell; sIL-2R, soluble IL-2R receptor; sIL-6R, 
soluble IL-6 receptor; TNF, tumor necrosis factor. 
 Table 2 .  Cellularity of biopsies from IBS patients compared to healthy subjects 
  Large intestine  Small intestine 
  Recto / Sigmoid  Descending  Transverse  Ascending  Cecum  Ileum  Jejunum  Duodenum 
 IEL  ↑ ( 49,64 ) 
 ↔ ( 51,63 ) 
 ↑ ( 49 )  ↑ ( 49 )  ↑ ( 49 )  ↔ ( 37,50 )   ↑ ( 60 ) 
 ↔ ( 41 ) 
 ↑ ( 59 ) 
 Mast  ↑ ( 61,81,91 ) 
 ↓ ( 67 ) 
 ↔ ( 48,49,51,57,63,66 ) 
 ↑ ( 44,52 – 56,66 ) 
 ↓ ( 62,67 ) 
 ↔ ( 48,49 ) 
 ↔ ( 49 )  ↑ ( 61 ) 
 ↔ ( 48,49,62 ) 
 ↑ ( 37,48,50 )  ↑ ( 57,58,61 )  ↑ ( 41,42,60 )  ↑ ( 59 ) 
 T (CD3)  ↑ ( 49,51,63,64,81 ) 
 ↔ ( 91 ) 
 ↑ ( 49,53 ) 
 ↔ ( 62 ) 
 ↑ ( 49 )  ↑ ( 49 ) 
 ↔ ( 62 ) 
 ↑ ( 50 )    
 T H  ↔ ( 91 )  ↑ ( 53 )       
 T C  ↑ ( 64 ) 
 ↔ ( 49,91 ) 
 ↑ ( 53 ) 
 ↓ ( 62 ) 
 ↔ ( 49 ) 
 ↔ ( 49 )  ↔ ( 49,62 )     
 B   ↔ ( 53 )       
 NK  ↔ ( 49 )  ↔ ( 49 )  ↔ ( 49 )  ↔ ( 49,62 )     
 Macrophage  ↓ ( 64 )  ↓ ( 62 )       
 Neutrophil  ↔ ( 49 )  ↔ ( 49 )  ↔ ( 49 )  ↔ ( 49 )  ↔ ( 50 )    
 Eosinophil      ↔ ( 37,50 )    
 IEL, intraepithelial lymphocyte; IBS, infl ammatory bowel syndrome; NK, natural killer cell; T C , cytotoxic T cell; T H , helper T cell. 
 This table demonstrates the confl icting nature of studies of IBS populations. The majority of these studies do not differentiate between IBS subgroups. 
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 B cells 
 Circulating B cells are also more likely to express the GI hom-
ing integrin  β 7 in IBS patients compared with healthy subjects; 
however, numbers of B cells are unchanged in the descending 
colon ( Figure 1 and  Table 2 ) ( 53,78,104 ). A greater proportion 
of B cells express the activation markers CD80 and CD86, and 
T-cell activation induces increased release of cytokines involved 
in B-cell activation in IBS compared with health ( 68,78 ). Th e 
primary role of B cells is to produce antibodies (Ig) directed 
against antigen, and IgG-positive B cells are increased in the 
blood of IBS patients relative to healthy subjects ( 68 ). Increased 
blood IgE and IgG concentrations are classically associated with 
allergy and are typically unaltered in IBS at baseline; however, 
in response to allergen serum IgE and IgG levels increase in 
IBS patients above that observed in health ( 37,70,71 ). Interest-
ingly, increased levels of autoantibodies against neuronal chan-
nels have been observed in IBS patients; however, the clinical 
implications of this are yet to be determined ( 105,106 ). Indeed, 
patients with autoimmune diseases, including Sjogren ’ s syn-
drome and type 1 diabetes, produce autoantibodies that aff ect 
GI motility via actions on calcium channels or muscarinic 
receptors, indicating a potential for autoantibody-mediated GI 
neural dysfunction ( 107,108 ). 
 IMMUNE MEDIATORS MODULATE COLONIC NERVE 
FUNCTION 
 As outlined above, mast cells and bacterial-derived mediators, 
such as serine proteases, are increased in IBS and activate colonic 
nerves, highlighting a potential role in symptoms ( Figure 2 ). 
Cytokines are important signaling messengers in the immune 
system, but also modulate nerve function. Indeed, TNF- α , IL-1 β , 
and IL-6 each sensitize colonic aff erent and enteric nerves 
( Figure 2 ) ( 87,109 – 112 ). Interestingly, we recently showed dif-
ferent functional eff ects of these cytokines on colonic sensory 
aff erents, whereby TNF- α caused a pronounced sensitization 
to mechanical stimuli, which was mediated by an interaction 
between TNFR1 and transient receptor potential A1 ( 43 ). IL-1 β 
and IL-6 had more subtle eff ects on sensitivity to mechanical 
stimuli, but IL-1 β caused pronounced chemosensory eff ects in 
the absence of distension, which were dependent on tetrodo-
toxin-sensitive sodium channels, but not on transient receptor 
potential A1 ( 43 ). Th ese fi ndings indicate cytokine receptors 
couple to diff erent eff ector channels, most likely by diff erent 
intracellular signaling pathways ( Figure 2 ). Peripheral blood 
mononuclear cells from IBS-D patients have high concentra-
tions of these cytokines, and we have also shown peripheral 
blood mononuclear cell supernatants from these patients sen-
sitize colorectal sensory nerves to distension ( 57,85,87,113 ). 
Further, TNF- α , IL-1 β , and IL-6 concentrations in peripheral 
blood mononuclear cells correlate with symptom severity in 
IBS-D, including the intensity and frequency of painful events 
and motility-associated symptoms ( Table 1 ) ( 85,87 ). 
 Immune cells also synthesize and secrete mediators that inhibit 
neuronal activity, including the opioids  β -endorphin, enkephalin, 
and dynorphin ( 114,115 ). Th ese mediators are endogenous ago-
nists of  μ -,  κ -, and  δ -opioid receptors, respectively, each of which 
is expressed on extrinsic sensory aff erent and / or enteric nerves 
( 116 ). Weak  μ -opioid receptor agonists are useful for treating 
diarrhea, whereas constipation is a common side eff ect of stronger 
pain-relieving opioids. In sensory aff erents, immune-derived 
 β -endorphin is particularly relevant in health, where it acts to 
set the threshold to nociceptive distension ( 87,117 ). Th us, loss of 
the inhibitory eff ect provided by immune-derived  β -endorphin 
potentially contributes to painful sensations, as nociceptive nerves 
become more easily activated, and also to motility alterations via 
activity on enteric neurons. 
 CONCLUSIONS 
 Despite several decades of promising evidence implicating the 
immune system in IBS, the extent to which it is involved in 
clinical symptoms remains controversial and many questions 
remain. Foremost is causation; what is driving the immune 
activation — is it centrally or peripherally mediated, or a combi-
nation of both? IBS patients frequently copresent with extrain-
testinal and psychological comorbidities, including anxiety 
and depression, which correlate with altered immune func-
tion ( Table 1 ), and emotional stimuli such as chronic stress 
are known to alter immune function (recently reviewed by 
Elsenbruch ( 118 )). If peripheral mechanisms dominate what is 
causing the immune activation — is it driven by food allergens, 
perturbations in microbiota, or bacterial or viral infection? 
Does an allergic- or autoimmune-type response predomi-
nate? What are the mechanisms underlying the interactions 
between the nervous and immune systems? Which effector 
ion channels and signaling pathways on peripheral nerves are 
most important? A major unanswered question is whether 
alterations driving the initial changes in neuroimmune signal-
ing are the same as those driving the maintenance of chronic 
symptoms. An integrated hypothesis could be that an initial 
peripheral insult drives changes in peripheral immune and 
nervous function, but also the central nervous system process-
ing of visceral stimuli. Altered central nervous system process-
ing may then modulate the descending innervation of the GI 
immune system, leading to enhanced susceptibility to luminal 
pathogens and chronic peripheral immune alterations, which 
in turn sensitize not only the peripheral nerves but also the 
central cognitive processes. 
 To answer these questions, much more information is required 
about both the immune system and the nervous system. Th e rela-
tionship between the host and the microbiome is only just begin-
ning to be investigated in detail, and given the major function 
dendritic cells have in antigen presentation in the gut, it would not 
be surprising if their function is altered in IBS. Pain is typically 
regarded as a danger signal and sign of disease, yet in GI diseases 
symptoms and pathology frequently correlate poorly. Much eff ort 
is made to identify mediators, eff ector channels, and pathways that 
activate neural endings; however, neuronal signaling is oft en a bal-
ance between excitatory and inhibitory factors. Loss of inhibitory 
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factors conceivably contributes to painful sensations, yet little is 
known of endogenous inhibitory mediators. Th e development 
and characterization of animal models of visceral hypersensitivity 
are clearly valuable in understanding how symptoms develop and 
persist, but as yet no animal model concurrently demonstrates all 
the symptoms of IBS. Little is known about changes in the periph-
eral nervous system in IBS patients, mainly due to the diffi  culty in 
accessing visceral neuronal tissue in humans; however, there have 
been recent promising studies characterizing human GI nerve 
functions ( 54,119,120 ). 
 Patient selection can clearly confound studies and more atten-
tion needs to be placed on the reporting of patient symptoms 
and similarities or diff erences between IBS cohorts, and also the 
adequate selection of control subjects. Diarrhea and constipation 
are diff erent extremes, and it is most likely that the underlying 
mechanisms diff er. Critical insights have been gained from follow-
ing post-infectious IBS patients, but it remains to be determined 
just how similar these patients are to non-post-infectious IBS. 
Complicating matters is the likelihood that IBS is multifactorial 
and patients may have alterations in several distinct underlying 
processes that may be linked, such as chronic stress and immune 
activation, or which may independently contribute to symptoms 
via distinct mechanisms. 
 Understanding how alterations in the neuroimmune axis lead 
to symptoms is critical to the development of new therapies for 
IBS. Th is requires a comprehensive knowledge of the nature of the 
changes in the immune system, and the subsequent modulation of 
viscerosensory and enteric nerve function by immune mediators. 
Answering these questions not only leads to new therapies but also 
potentially reveals causation, shift ing the classifi cation of IBS from 
a functional disease to an organic one. 
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